{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:49:28Z","timestamp":1740134968605,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Council Australia","award":["APP1041733"],"award-info":[{"award-number":["APP1041733"]}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["APP1041733"],"award-info":[{"award-number":["APP1041733"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4745-3","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:31:47Z","timestamp":1535560307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of ANZUP","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola J.","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Toner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danish","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzana","family":"Pashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Grimison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"key":"4745_CR1","volume-title":"SEER Cancer Statistics Review, 1975-2014","author":"NNA Howlader","year":"2017","unstructured":"Howlader NNA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2014. Bethesda, https:\/\/seer.cancer.gov\/csr\/1975_2014\/ , based on November 2016 SEER data submission, posted to the SEER web site, April: National Cancer Institute; 2017."},{"issue":"2","key":"4745_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","volume":"15","author":"International Germ Cell Cancer Collaborative Group","year":"1997","unstructured":"International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International germ cell Cancer collaborative group. J Clin Oncol. 1997;15(2):594\u2013603.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4745_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ygyno.2015.06.029","volume":"138","author":"JL Meisel","year":"2015","unstructured":"Meisel JL, Woo KM, Sudarsan N, Eng J, Patil S, Jacobsen EP, et al. Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol. 2015;138(3):566\u201372.","journal-title":"Gynecol Oncol"},{"key":"4745_CR4","first-page":"594","volume-title":"Comprehensive Textbook of Genitourinary Oncology","author":"PS Grimison","year":"2011","unstructured":"Grimison PS, Toner GC. Management of Advanced Germ Cell Tumors: IGCCC Intermediate- and Poor-Risk Patients. In: Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ, Rini BI, Bochner BH, et al., editors. Comprehensive Textbook of Genitourinary Oncology. 4e ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 594\u2013602.","edition":"4e"},{"issue":"30","key":"4745_CR5","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1200\/JCO.2006.06.2489","volume":"24","author":"N Murugaesu","year":"2006","unstructured":"Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862\u20136.","journal-title":"J Clin Oncol"},{"issue":"24","key":"4745_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djq409","volume":"102","author":"L Bonilla","year":"2010","unstructured":"Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102(24):1845\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4745_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626\u201333.","journal-title":"Blood"},{"issue":"33","key":"4745_CR8","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"RB Womer","year":"2012","unstructured":"Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's oncology group. J Clin Oncol. 2012;30(33):4148\u201354.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4745_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/annonc\/mdi264","volume":"16","author":"SA Gregory","year":"2005","unstructured":"Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol. 2005;16(9):1413\u201324.","journal-title":"Ann Oncol"},{"issue":"8","key":"4745_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ncponc0560","volume":"3","author":"R Simon","year":"2006","unstructured":"Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006;3(8):406\u20137.","journal-title":"Nat Clin Pract Oncol"},{"issue":"7","key":"4745_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrc1650","volume":"5","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5(7):516\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4745_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/annonc\/mdt369","volume":"25","author":"PS Grimison","year":"2014","unstructured":"Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, et al. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand urogenital and prostate Cancer trials group (ANZUP). Ann Oncol. 2014;25(1):143\u20138.","journal-title":"Ann Oncol"},{"issue":"12","key":"4745_CR13","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1093\/annonc\/mdw313","volume":"27","author":"N Lawrence","year":"2016","unstructured":"Lawrence N, Martin A, Toner G, Stockler M, Buizen L, Thomson D, et al. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand urogenital and prostate Cancer trials group (ANZUP). Ann Oncol. 2016;27(12):2302\u20133.","journal-title":"Ann Oncol"},{"key":"4745_CR14","volume-title":"Common Toxicity Criteria for Adverse Events v4.03 (CTCAE)","author":"National Cancer Institute Cancer Therapy Evaluation Program (CTEP)","year":"2009","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program (CTEP). Common Toxicity Criteria for Adverse Events v4.03 (CTCAE) 2009."},{"issue":"5","key":"4745_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European-organization-for-research-and-treatment-of-Cancer Qlq-C30 - a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4745_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11136-012-0147-1","volume":"22","author":"B Holzner","year":"2013","unstructured":"Holzner B, Efficace F, Basso U, Johnson CD, Aaronson NK, Arraras JI, et al. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2013;22(2):369\u201378.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehab"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4745-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4745-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4745-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:37:15Z","timestamp":1693849035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4745-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4745"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4745-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2018,8,29]]},"assertion":[{"value":"14 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the Sydney Local Health District (RPAH zone, HREC\/13\/RPAH\/226) on 5th July 2013. This provided central ethics approval. Local ethical approval has been obtained for all participating centres. The study will be performed in accordance with the Declaration of Helsinki and satisfy the regulatory requirements in Australia, United Kingdom and United States of America. Written informed consent was obtained from all patients included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"854"}}